Could Innovation Proficiency Improve Biopharma's Broken Image?
Source: Life Science Leader
By Rita Gunther McGrath
A big part of the innovation challenge for large pharma companies is that, while researchers are very good at technical innovation, the business end is not. This has to do with the reality that for most of the industry’s existence, once a compound shows efficacy, the rest of the business relies on rapid execution of getting that drug out the door as fast as possible. This results in a real lack of imagination on the part of many pharma executives with respect to how they can create compelling (and therefore premium-priced) value for their customers.
VIEW THE MAGAZINE ARTICLE!
Log In
Signing up provides unlimited access to:
Free Sign Up

Signing up provides unlimited access to:
- Trend and Leadership Articles
- Case Studies
- Extensive Product Database
- Premium Content
HELLO. PLEASE LOG IN.
X
Not yet a member of Life Science Leader? Register today.
ACCOUNT SIGN UP
X
Please fill in your account details
ACCOUNT SIGN UP
This website uses cookies to ensure you get the best experience on our website. Learn more